Improving outcomes in pediatric autoimmune liver disease
Autoimmune Liver Disease Network for Kids (A-LiNK): Using Patient Data to Transform Care and Improve Outcomes for Children, Adolescents, and Young Adults With Autoimmune Liver Disease
This study is trying to improve care for kids with autoimmune liver diseases by collecting and sharing information about their treatments and health to help doctors provide better support.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati Academic / other |
| Locations | 8 sites (Palo Alto, California and 7 other locations) |
| Trial ID | NCT05750498 on ClinicalTrials.gov |
What this trial studies
The Autoimmune Liver disease Network for Kids (A-LiNK) aims to enhance care for children with autoimmune liver diseases by establishing a shared clinical registry and a learning health network. This observational study focuses on collecting and sharing clinical data and treatment processes among participating institutions. By addressing the unique challenges of Pediatric Autoimmune Hepatitis and Primary Sclerosing Cholangitis, the study seeks to standardize monitoring and management practices, ultimately improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include children diagnosed with autoimmune hepatitis, primary sclerosing cholangitis, or autoimmune sclerosing cholangitis.
Not a fit: Patients with a history of liver transplant will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could lead to better management and treatment strategies for children suffering from autoimmune liver diseases.
How similar studies have performed: Other studies focusing on collaborative networks for chronic diseases have shown success in improving patient outcomes, suggesting a positive outlook for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of autoimmune hepatitis (AIH) * Clinical diagnosis of primary sclerosing cholangitis (PSC) * Clinical diagnosis of autoimmune sclerosing cholangitis (ASC) Exclusion Criteria: • History of liver transplant
Where this trial is running
Palo Alto, California and 7 other locations
- Stanford University — Palo Alto, California, United States (Recruiting)
- Riley Children's Health — Indianapolis, Indiana, United States (Recruiting)
- St. Louis Children's Hospital — St Louis, Missouri, United States (Recruiting)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (Recruiting)
- Nationwide Children's Hospital — Columbus, Ohio, United States (Recruiting)
- UPMC Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States (Recruiting)
- UT Southwestern Medical Center — Dallas, Texas, United States (Recruiting)
- Seattle Children's Hospital — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Amy E Taylor, MD — Children's Hospital Medical Center, Cincinnati
- Study coordinator: Amy E Taylor, MD
- Email: amy.taylor@cchmc.org
- Phone: 513-636-4415
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.